Pfizer ($PFE) is poised to strike a collaborative deal on preclinical research and development with South Africa's North-West University. The partnership may include the use of Pfizer's genetically modified animal models to evaluate the safety and efficacy of therapeutic molecules in oncology, inflammation, immunology, central nervous system and cardiovascular system disorders. Pfizer and North-West University are still discussing the terms of the deal with a final agreement pending. The deal signals Pfizer's interest in capitalizing on emerging markets and reflects a growing trend of academic and industry partnership in drug discovery and development. Release